Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vofatamab |
| Trade Name | |
| Synonyms | B-701|MFGR1877S|RG-7444|R3Mab |
| Drug Descriptions |
Vofatamab (B-701) is a monoclonal antibody, which binds FGFR3 to prevent phosphorylation and signaling, thereby inhibiting proliferation and promoting apoptosis in cancer cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534, PMID: 22203368). |
| DrugClasses | FGFR3 Antibody 5 |
| CAS Registry Number | 1312305-12-6 |
| NCIT ID | C116863 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| 225Ac-FPI-1966 + Vofatamab | 225Ac-FPI-1966 Vofatamab | 0 | 1 |
| Atezolizumab + Vofatamab | Atezolizumab Vofatamab | 0 | 1 |
| Docetaxel + Vofatamab | Docetaxel Vofatamab | 2 | 1 |
| Pembrolizumab + Vofatamab | Pembrolizumab Vofatamab | 0 | 1 |
| Vofatamab | Vofatamab | 8 | 1 |